Finance

Lists
TENX:NASDAQ
Tenax Therapeutics Inc
$1.80
-1.64%
(-0.030) 1D
$1.80
0.00% (0.00)
After hours
Closed: Aug 14, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TENX...
Open
$1.77
High
$1.87
Low
$1.71
Mkt. cap
67.36M
Avg. vol.
5.42M
Volume
5.84M
52-wk high
$19.40
52-wk low
$1.31
EPS
-$1.47
Beta
0.93
Shares outstanding
37.42M
No. of employees
15
Open
$1.77
High
$1.87
Low
$1.71
Mkt. cap
67.36M
Avg. vol.
5.42M
Volume
5.84M
52-wk high
$19.40
52-wk low
$1.31
EPS
-$1.47
Beta
0.93
Shares outstanding
37.42M
No. of employees
15
News stories
From web sources and news partners
About Tenax Therapeutics Inc
CEOChris Giordano
Employees15
Founded1967
Headquarters-
SectorBiotechnology
Websitetenaxthera.com
Analyst ratings
Based on 10 analysts giving stock ratings to TENX in the past 3 months
Buy
Buy
7
Hold
3
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for TENX in the last 3 months.
Highest
Current $1.80
$35.00 (+1,844.44%)
Average
$9.00 (+400.00%)
Lowest
$4.00 (+122.22%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$14.00
+677.8%
08/12/2026
Gautam Chukka
Chardan Capital
Hold
Downgraded
$5.00
+177.8%
08/11/2026
Angela Qian
Canaccord Genuity
Buy
Maintained
$4.00
+122.2%
08/11/2026
Seamus Fernandez
Guggenheim
Buy
Maintained
$4.00
+122.2%
08/11/2026
David Risinger
Leerink Partners
Buy
Maintained
$4.00
+122.2%
08/11/2026
Gaurav Maini
LifeSci Capital
Buy
Maintained
$5.00
+177.8%
08/10/2026
Gavin Clark-Gartner
Evercore ISI
Hold
Downgraded
$5.00
+177.8%
08/10/2026
Matt Phipps
William Blair
Hold
Downgraded
-
-
08/10/2026
Jonathan Aschoff
Roth MKM
Buy
Maintained
$5.00
+177.8%
08/10/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$35.00
+1,844.4%
07/29/2026
Unknown Analyst
Canaccord Genuity
Buy
Initiated
$35.00
+1,844.4%
07/28/2026
Unknown Analyst
Chardan Capital
Buy
Initiated
$27.00
+1,400%
06/22/2026
Unknown Analyst
Roth MKM
Buy
Maintained
$30.00
+1,566.7%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.33M
10.54M
11.54M
12.85M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.48M
5.91M
5.03M
5.93M
Operating expense
16.81M
16.45M
16.57M
18.78M
Total operating expenses
16.81M
16.45M
16.57M
18.78M
Operating income
-16.81M
-16.45M
-16.57M
-18.78M
Other non operating income
-15.00K
-9.00K
-4.00K
-
EBT including unusual items
-15.80M
-15.54M
-15.72M
-17.80M
EBT excluding unusual items
-15.80M
-15.54M
-15.72M
-17.80M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.80M
-15.54M
-15.72M
-17.80M
Net profit margin
-
-
-
-
Earnings per share
-0.40
-0.38
-0.35
-0.35
Interest and investment income
1.02M
918.00K
861.00K
981.00K
Interest expense
-
-
-
-
Net interest expenses
1.02M
918.00K
861.00K
981.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps